Show simple item record

dc.contributor.authorSchöffski, P
dc.contributor.authorSufliarsky, J
dc.contributor.authorGelderblom, H
dc.contributor.authorBlay, J
dc.contributor.authorStrauss, S
dc.contributor.authorStacchiotti, S
dc.contributor.authorRutkowski, P
dc.contributor.authorLindner, L
dc.contributor.authorLeahy, Michael G
dc.contributor.authorItaliano, A
dc.contributor.authorIsambert, N
dc.contributor.authorDebiec-Rychter, M
dc.contributor.authorSciot, R
dc.contributor.authorVan Cann, T
dc.contributor.authorMarréaud, S
dc.contributor.authorNzokirantevye, A
dc.contributor.authorCollette, S
dc.contributor.authorWozniak, A
dc.date.accessioned2018-06-27T20:09:38Z
dc.date.available2018-06-27T20:09:38Z
dc.date.issued2018-06
dc.identifier.citationCrizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. 2018, 6(6): 431-441 Lancet Respir Meden
dc.identifier.issn2213-2619
dc.identifier.pmid29669701
dc.identifier.doi10.1016/S2213-2600(18)30116-4
dc.identifier.urihttp://hdl.handle.net/10541/621060
dc.description.abstractAn inflammatory myofibroblastic tumour (IMFT) is a rare mesenchymal neoplasm characterised by anaplastic lymphoma kinase (ALK) gene rearrangements. We assessed the activity and safety of crizotinib, a tyrosine kinase inhibitor, targeting ALK in patients with advanced IMFT either with or without ALK alterations.
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Respiratory medicineen
dc.titleCrizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.en
dc.typeArticleen
dc.contributor.departmentDepartment of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgiumen
dc.identifier.journalThe Lancet Respiratory Medicineen
html.description.abstractAn inflammatory myofibroblastic tumour (IMFT) is a rare mesenchymal neoplasm characterised by anaplastic lymphoma kinase (ALK) gene rearrangements. We assessed the activity and safety of crizotinib, a tyrosine kinase inhibitor, targeting ALK in patients with advanced IMFT either with or without ALK alterations.


Files in this item

This item appears in the following Collection(s)

Show simple item record